Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/27773
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 16766/19061 (88%)
造訪人次 : 5995889      線上人數 : 223
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: http://ir.cnu.edu.tw/handle/310902800/27773


    標題: An HDAC inhibitor enhances cancer therapeutic efficiency of RNA polymerase III promoter-driven IDO shRNA
    作者: Yen, M-C
    Weng, T-Y
    Chen, Y-L
    Lin, C-C
    Chen, C-Y
    Wang, C-Y
    Chao, H-L
    Chen, C-S
    Lai, M-D
    貢獻者: 老人服務事業管理系
    關鍵字: H1 Promoter
    Ido Shrna
    Indoleamine 2,3-Dioxygenase
    Osu-Hdac42
    Rna Polymerase Iii
    U6 Promoter
    日期: 2013-06
    上傳時間: 2014-05-26 10:43:05 (UTC+8)
    出版者: Nature Publishing Group
    摘要: Histone deacetylase (HDAC) inhibitors are used in treating certain human malignancies. Our laboratories demonstrated their capability in enhancing antitumor effect of DNA vaccine driven by an RNA polymerase II (RNA pol II) promoter. However, it is unknown whether HDAC inhibitors enhance the therapeutic short hairpin RNA (shRNA) expressed by an RNA polymerase III (RNA pol III) promoter. We investigated whether HDAC inhibitors augmented antitumor effect of indoleamine 2,3 dioxygenase (IDO) shRNA. HDAC inhibitor OSU-HDAC42 and suberoylanilide hydroxamic acid enhanced RNA pol III-driven U6 and H1 promoter activity in three different cell types in vitro: 293, NIH3T3 and dendritic cell line DC2.4. Subcutaneous injection of OSU-HDAC42 enhanced U6 and H1 promoter activity on abdominal skin of mice in vivo. Combination of IDO shRNA and OSU-HDAC42 increased antitumor effect of IDO shRNA in MBT-2 murine bladder tumor model. IDO shRNA induced tumor-infiltrating CD8(+) and CD4(+) T cells, whereas OSU-HDAC42 treatment induced tumor-infiltrating CD4(+) T cells. Combination of OSU-HDAC42 and IDO shRNA further induced tumor-infiltrating natural killer cells and enhanced interferon-gamma in lymphocytes, but suppressed interleukin (IL)-4 expression of lymphocytes. In addition, OSU-HDAC42 treatment did not alter mRNA expression of IL-12 and tumor necrosis factor-alpha. In conclusion, HDAC inhibitor OSU-HDAC42 may serve as adjuvant of the therapeutic shRNA expressed by an RNA pol III promoter.
    關聯: Cancer Gene therapy, v.20 n.6, pp.351-357
    顯示於類別:[老人服務事業管理系] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    index.html0KbHTML679檢視/開啟


    在CNU IR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋